He is a key opinion leader for Galderma, and currently the chief medical and scientific officer of a UK ABPI registered biopharmaceutical company developing a platform for the treatment of Alzheimer’s disease.

He has recently presented a lecture on neurotoxins at Aesthetic Conference UK in 2019 and worked closely with Saatchi and Saatchi on improving awareness of neurotoxins to clinicians and the public.

He is the chairman of the Association of PDO threads UK and chairs the UK’s largest Aesthetic Conference (FACE) on their threads agenda.

Alongside his medical practice he has been working in the field of anti-ageing and aesthetics for over a decade. He has co-ordinated and overseen two MHRA registered phase IIa double blind placebo controlled clinical trials undertaken in the UK. He notably achieved the successful award of an Orphan Drug Designation from the US FDA in 2014.

Prof. Haq has worked closely with PwC and Rothschilds in the past, as part of a biopharma valuation process and with Vertex Pharmaceuticals.

Prof. Haq trained at Guy’s Hospital, Hammersmith and the Royal Brompton Hospitals, Imperial College University, Massachusetts General Hospital, Harvard Medical School, and Tufts University in Boston. Following his medical training he completed a PhD at Harvard Medical School/Mass General in the field of cell signal transduction. The cutting-edge work has provided insight into how cells communicate, age and have led to the development of a series of signal effector inhibitors.

He has published over 100 peer-reviewed scientific articles/abstracts in e.g., Proceedings of the National Academy of Science, Ann Rheum Diseases, Journal of Clinical Investigations, Circulation, Arthritis Research and Therapy, and Nature Medicine. He has received multiple national and international awards/ fellowships/honours from the Medical Research Council, Welcome Trust, Zeneca Pharmaceuticals, American Heart Association, Heart Failure Society of America.